Abstract
Technetium-99m-d,l-hexamethylpropylene amine oxime (Tc-99m-HMPAO) has been developed in our Institute in order to meet the demand of GDR clinicians for a radiopharmaceutical, which allows the examination of regional cerebral blood-flow by SPECT. The present paper informs on synthesis and 13C NMR spectroscopic identification of the ligand d,l-HMPAO as well as its labelling by reconstitution of a sterile, freeze-dried mixture containing d,l-HMPAO, stannous chloride, and sodium chloride with Tc-99m-pertechnetate eluate. Labelling efficiency (more than 90%, the lipophilic component 80–90%) and pattern of products were estimated using tlc and paper chromatography with a combination of three solvent systems. Quality control of the freeze-dried formulation includes methods for quantitative determination of the ligand and of stannous chloride. The ability of Tc-99m-HMPAO to be localized in brain was quantified in rats by organ distribution with time and by autoradiography, showing both high initial uptake, and bl...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Isotopenpraxis Isotopes in Environmental and Health Studies
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
